Back to News
Market Impact: 0.25
AstraZeneca, Oracle Launch AI Collaboration To Optimise Clinical Trials
Source: Nasdaq
Artificial IntelligenceHealthcare & BiotechTechnology & Innovation
AstraZeneca and Oracle Health & Life Sciences launched a global AI collaboration focused on improving clinical-trial recruitment, earlier disease diagnosis, drug-safety monitoring and the use of real-world evidence. The article provides no financial terms, timelines or expected commercial impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
AZN0.55
ORCL0.55
More News
- AI rally fades away from Wall Street as a tiny IPO makes big waves
- Wedbush’s Ives reiterates Outperform on SpaceX stock citing SI growth
- Apple shares aren't cheap. Here's how to get long for less
- Investors hedge AI boom with credit default swaps on tech debt
- TEZSPIRE positive results from Phase III CROSSING trial in eosinophilic esophagitis including symptom improvement, histologic and endoscopic remission presented at United European Gastroenterology Week
- Accenture acquires construction tech consultancy Avicado